(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Horses really can smell our fear, new study finds - 2War in Iran could exacerbate German housing crisis, minister warns
- 3When the moon hits your eye from your Orion ship up high, that's a 'mare'
- 4The Main 15 Applications for Efficiency and Association
- 5Poland identifies two Ukrainian suspects in railway sabotage blast
- Vote in favor of Your Number one kind of pie
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- Family Holiday spots
- 6 Arranging Administrations to Change Your Open air Space
- Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- Rick Steves Doesn't Want You Overlooking This Food Spot While In France
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
